Carbapenem-Resistant Enterobacteriaceae

Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing En...

Full description

Saved in:
Bibliographic Details
Published inClinics in laboratory medicine Vol. 37; no. 2; p. 303
Main Authors Iovleva, Alina, Doi, Yohei
Format Journal Article
LanguageEnglish
Published United States 01.06.2017
Subjects
Anti-Bacterial Agents - therapeutic use
beta-Lactam Resistance
beta-Lactamases - biosynthesis
Carbapenems - therapeutic use
Enterobacteriaceae - drug effects
Enterobacteriaceae - enzymology
Microbial Sensitivity Tests
Rapid diagnosis
Carbapenemase
KPC
Online AccessGet more information

Cover

More Information
Summary:Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.
ISSN:1557-9832
DOI:10.1016/j.cll.2017.01.005